Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  2008-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.23490PMID 18438878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status.

  2004cited by this paper
• The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

  2002cited by this paper
• Targeting the epidermal growth factor receptor for cancer therapy.

  2002cited by this paper
• Chemoprevention of breast cancer: a model for change.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification

  1992cited by this paper
• Cancer statistics

  1989cited by this paper

• A Case of Osimertinib-Induced Eosinophilic Pneumonia.

  2022cites this paper
• Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit

  2022cites this paper
• Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

  2021cites this paper
• CMAR_A_322967 7187..7201

  2021cites this paper
• Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants

  2020cites this paper
• The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer

  2020cites this paper
• Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

  2019cites this paper
• Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

  2018cites this paper
• Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?

  2017cites this paper
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors

  2017cites this paper
• From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

  2015cites this paper
• Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

  2014cites this paper
• Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.

  2013cites this paper
• Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

  2012cites this paper
• Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

  2012cites this paper
• Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.

  2011cites this paper
• Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

  2011cites this paper
• Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.

  2011cites this paper
• Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer

  2011cites this paper
• Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

  2010cites this paper
• Profilo mutazionale degli oncogeni EGFR e KRAS in cellule di carcinoma broncogeno non-a-piccole cellule ottenute da Fine needle aspiration cytology (FNAC)

  2010cites this paper
• Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

  2010cites this paper
• Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors

  2010cites this paper
• Update on Anti-EGFR Targeted Therapy

  2009cites this paper
• Update on Anti-EGFR Therapy

  2009cites this paper
• Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer

  2009cites this paper
• Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.

  2009cites this paper
• The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC

  2009cites this paper
• Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

  2009cites this paper